FDA approves second West Nile Virus test

The U.S. Food and Drug Administration has approved a second screening test for West Nile Virus disease for use in donated blood and organs.

The cobas TaqScreen WNV test is an automated test that's able to detect the genetic material of the virus itself early during the infection process, the FDA said. The nucleic acid testing detects whether donated blood and organs have been infected, even if the donor's body hasn't begun to produce antibodies against the virus.

West Nile Virus is most often transmitted to humans by mosquitoes but it can also be transmitted through blood transfusion or organ transplantation from infected donors.

The approval means blood centers and hospitals will have a choice of two FDA-approved tests, said Dr. Jesse Goodman, director of the FDA's Center for Biologics Evaluation and Research.

The newly approved test is manufactured by Roche Molecular Systems Inc. of Pleasanton, Calif.

Copyright 2007 by United Press International


Explore further

Biomarker may aid in determining treatment for cancer patients

Citation: FDA approves second West Nile Virus test (2007, August 29) retrieved 10 December 2019 from https://medicalxpress.com/news/2007-08-fda-west-nile-virus.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments